

TRANSACTIONAL ADVISORY

CDMO



Bourne Partners served as the exclusive financial advisor to Avista Pharma Solutions, a contract development, manufacturing, and testing organization, in its sale to Cambrex Corporation (NYSE: CBM), the leading fully integrated small molecule CDMO across the entire drug lifecycle, for \$252 million. The transaction closed on January 2, 2019.

PHARMA



Bourne Partners facilitated and sourced the eventual buyer of Endo International plc's Huntsville, Alabama pharma manufacturing and packaging facility. A consortium lead by Federal Equipment Company purchased the manufacturing site in Q4 2018.

PHARMA



Bourne Partners served as the exclusive financial advisor to Endo International plc in the sale of 24 generic products to Lannett Company, Inc. The portfolio of products was sold for an undisclosed amount on May 7, 2018.

CRO



Bourne Partners served as the exclusive sell-side advisor to Accelovance Inc., a clinical CRO, in the sale of the company's remaining assets to Linical Co. for \$32 million. The transaction closed on April 16, 2018.

CDMO



Bourne Partners served as the buy-side advisor to The Carlyle Group in its acquisition of Albany Molecular Research, Inc., a global, full-service CDMO, for \$1.62 billion. The transaction closed on August 31, 2017.

CROSSMO



Bourne Partners served as the exclusive financial advisor to leading middle-market CRO, Accelovance, Inc., in the sale of its Site Management Organization (SMO), Optimal Research. Optimal Research was sold to Synexus, part of PPD's Accelerated Enrollment Solutions business unit, for an undisclosed amount in Q4 2017.

CHOTC



Bourne Partners served as the exclusive financial advisor to medical science and technology company, Prophase Labs, Inc. in the sale of its flagship brand, Cold-EEZE®, to Mylan N.V. for \$50 million. The transaction closed on March 29, 2017.

CURRENT M&A PIPELINE

Representative Current Retained Sell-Side And Partnering Opportunities

Project Capture

Sell-side | Southeastern US | Consumer Health | Prescription drug disposal and opioid abuse deterrent solution

Project Fusion

Licensing Partnership | US Rights | Medical Device | International product expecting FDA approval Q2 2019

** To request more information on the opportunities above, please contact: Tucker Ammons | tammons@bourne-partners.com | 704.714.8357

STRATEGIC CAPITAL

P
B
M



Bourne Partners Strategic Capital (“Bourne”), alongside The Carlyle Group, invested in WellDyneRx, a full-service prescription benefit manager (PBM) with a network of over 65,000 pharmacies. WellDyneRx targets the acquisition of other PBMs and related businesses.

C
D
M
O



Bourne, alongside The Carlyle Group, invested in Albany Molecular Research, Inc. (“AMRI”), a contract research and manufacturing company. The US-based CDMO seeks global acquisition opportunities in niche, hard-to-make, biologic, and related categories.

R
X
-
O
T
C



Bourne, alongside The Carlyle Group, invested in iNova Pharma, a contract development and manufacturing organization. The Australian-based specialty pharmaceutical company seeks acquisition and in-licensing opportunities in Asia/Pacific markets (primarily Australia, South/Southeast Asia, and South Africa).

R
X
-
G
X



Bourne invested in Novitium Pharma, a privately held generic pharmaceutical company. Novitium seeks to acquire established generic and generic pipeline assets, and will also review compelling manufacturing acquisition opportunities.

P
H
A
R
M
A



Bourne, alongside The Carlyle Group and other pharma veterans, jointly launched and invested in Millicent Pharma. Millicent Pharma seeks to build a global end-to-end pharmaceutical company through acquisition and the development of acquired pharmaceutical products.

PHILANTHROPY



In August 2018, Banks Bourne (CEO of Bourne Partners) and Rob Keel (Director of TannerMAP) joined The Max Foundation on a fundraising journey to Uganda to help bridge the “last mile” of treatment access for cancer patients. While in Uganda, they attended the #MaxLastMile Symposium in Entebbe and met with patients, partners, and doctors to discuss the future of treatment access.

WHY BOURNE PARTNERS?

Bourne Partners is an investment banking advisory and strategic capital investment firm with 17 years of transactional experience focused exclusively in the Healthcare and Pharma Services, Pharma and Consumer Health sectors.

We're a leader in these sectors having worked with many of the top global strategic and financial investors. [Our team](#) completed over \$6B of transactions in the last 3 years, and have a long track record of maximizing outcomes for clients on M&A, Capital Sourcing and Strategic Partnering mandates (*select clients and counterparties represented below*).

Also, as owners and operators in these sectors, we often serve as a value-added investor partner beside brand name Private Equity (The Carlyle Group, Cerberus Capital Management L.P., and others).

To learn more, please visit our website: www.bourne-partners.com

